Navigation Links
Shionogi Inc. Announces Commercial Availability of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD
Date:1/10/2011

FLORHAM PARK, N.J., Jan. 10, 2011 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY™, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.  KAPVAY™ is the first and only FDA-approved ADHD treatment indicated for use as add-on therapy to stimulant medication, in addition to use as monotherapy.

"Shionogi is extremely proud to bring KAPVAY™ to market in the U.S.," said Donald C. Manning, MD, PhD, Chief Medical Officer of Shionogi Inc.  "The extended-release version of clonidine hydrochloride found in KAPVAY™ offers an exciting new treatment option for children and adolescents with ADHD who are not experiencing adequate symptom relief from stimulants alone."  

ADHD affects more than 4.5 million children in the U.S., with at least 7 percent of U.S. school-aged children believed to suffer from the condition.  Symptoms include difficulty in maintaining attention and focus and in controlling behavior, as well as hyperactivity/over-activity.  While stimulant medications remain a first line treatment for ADHD, up to 30 percent of ADHD patients do not achieve an optimal response to stimulant monotherapy.

KAPVAY™'s recent FDA approval was based on two Phase III studies, which demonstrated significant efficacy at Week 5 in children and adolescents (6-17 years) with ADHD treated with KAPVAY™.  Signs and symptoms of ADHD were evaluated using the investigator administered and scored ADHD Rating Scale-IV-Parent Version (ADHDRS-IV) total score, including hyperactive/impulsivity and inattentive subscales.  Treatment-emergent adverse events, such as somnolence and fatigue, were mostly mild to moderate. Thirteen percent (13%) of patients
'/>"/>

SOURCE Shionogi Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
2. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
3. BioCrysts Partner Shionogi Launches Peramivir In Japan Under The Name RAPIACTA
4. Shionogi Enters Into Exclusive License Agreement With QuatRx Pharmaceuticals To Market Ospemifene
5. Shionogi Inc. Announces FDA Approval of CUVPOSA™ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
6. Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PRINCETON, N.J. , Dec. 24, 2014 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today that on ... registered public offering. The Company raised ... offering and intends to use the net proceeds ...
(Date:12/24/2014)...  Diplomat Pharmacy, Inc. (NYSE: DPLO ), ... announce Jennifer Hagerman , Pharm.D., AE-C, senior director ... as the president of the Michigan Pharmacists Association on ... place Feb. 28, 2015, at the MPA Annual Convention ... Center in Detroit, Michigan . Hagerman ...
(Date:12/24/2014)... PuraMed BioScience®, Inc., (OTC Pink: PMBS), a ... healthcare products, announced it received the initial funding to ... headache relief product, for planned distribution to 1,000 medical ... , Washington State , and ... H Advanced headache relief gel formulation completed, PuraMed BioScience ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... Calif., April 4, 2011 ICU Medical, ... three different clinical studies presented at the Annual Scientific ... (SHEA) April 1-4 in Dallas showed that the MicroCLAVE ... of bacterial contamination and limit the incidence of hospital-acquired ...
... Hospital is planning to leverage Prognosis ChartAccess® Comprehensive EHR ... improving clinical care, meeting the government,s meaningful use requirements, ... Texas Regional Health Information Organization (RHIO). "Like ... at the same time meet the government,s requirements for ...
Cached Medicine Technology:Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections 2Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections 3Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections 4Hamlin Memorial Hospital Selects Prognosis ChartAccess® Comprehensive EHR 2Hamlin Memorial Hospital Selects Prognosis ChartAccess® Comprehensive EHR 3
(Date:12/25/2014)... York (PRWEB) December 25, 2014 Product ... DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to ... According to an Order issued in the U.S. District ... Court will convene an open conference on January 7, ... United States Courthouse in West Palm Beach, Florida. The ...
(Date:12/25/2014)... December 25, 2014 The short film “Color ... created in honor of a true 9/11 hero, Welles Remy ... festivals including the 24 hours of Nuremberg International Short Film ... , Actress, screenwriter and director Luciana Lagana ... film together with her husband, Gregory Graham - ...
(Date:12/25/2014)... December 25, 2014 When head lice hits ... in a frenzy to get rid of it while keeping ... in Coral Gables now have the solution right in their ... clinic location, Lice Troopers provides full spectrum head lice screening ... Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, ...
(Date:12/25/2014)... Overeating is common during the holidays, but there are strategies ... "Don,t arrive at a party hungry. It may seem ... attending a party, but deprivation leads to hunger, and hunger ... Hospital in Mount Kisco, N.Y., said in a hospital news ... and even to have a snack before attending a party ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... continue to move forward in a number of multidistrict ... of West Virginia, Bernstein Liebhard LLP reports. According to ... is scheduled to convene a Joint Status Conference in ... 10:00 a.m. Parties have been directed to submit a ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... 2 Regarding the completely fabricated,item about GO3 ... July 14, 2008,edition of Star magazine, none of ... were contacted by the magazine prior to publication., ... reviewing its legal options and will vigorously pursue ...
... distant sites has a poor prognosis, but an experimental drug ... in some patients, a research team led by investigators from ... in the July 3rd edition of The New England ... is a VEGF inhibitor, a biologic agent that targets receptors ...
... light of today,s,announcement that Attorney General Mike Cox is ... the Coalition for a Fair and,Competitive Insurance Market is ... Blue Cross Blue Shield of Michigan (BCBSM) to use ... and insurance., "We were confident when we raised ...
... a genetic mutation that improves response to therapy , , ... that inhibits tumor blood vessel formation slows the progression ... study finds. , Of the 93 patients with rapidly ... with motesanib diphosphate. Of those 49 patients, 14 percent ...
... LAVAL, QC, July 2 /PRNewswire-FirstCall/ - Labopharm Inc. ... submitted a complete response to,the Food and Drug ... M.D., the FDA,s Deputy Director, Center for Drug ... the regulatory path towards,potential U.S. approval of the ...
... MD, will join three other physicians as a 2008 American Orthopaedic ... ... Orlando, Florida (PRWEB) July 2, 2008 -- University of ... physicians as a 2008 American Orthopaedic Society for Sports Medicine ...
Cached Medicine News:Health News:GO3 Statement Regarding Erroneous Coverage in Star Magazine 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 3Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 4Health News:Coalition Calls on MI Legislature to Abandon Blue Cross Legislation 2Health News:New Drug Slows Thyroid Cancer 2Health News:Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 3
... Ultrasonic Nebulizer has an easy-to-operate ... portable, and lightweight unit is ... quite treatments operating on AC ... auto adapter. , ,Optional ...
With ten colors available, Spectrums line of Color-Coded Fiberoptic Light Cables makes it easy to track by department....
Lumitex® LightMat® Surgical Illuminator improves visualization in deep cavity surgery. Flexible and malleable, it attaches easily to most retractors, bringing bright, cool area lighting where...
... The new UltraLux headlight gives you the ... can afford. It offers the illumination, comfort and ... The UltraLux is our lightest headlight. It features ... 130 for unsurpassed comfort and flexibility. Now when ...
Medicine Products: